Taiho Oncology, Inc.
- FDA Approves Lonsurf (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - February 25, 2019
- FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer - September 22, 2015
- Taiho Oncology, Inc. Announces TAS-102 NDA for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA - February 23, 2015
Drugs Associated with Taiho Oncology, Inc.
Taiho Oncology, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.